Replies to post #206079 on Biotech Values

[DewDiligence]

ABBV/ENTA—There are about a million patients on dialysis between the 3 major markets (US EU JPN), so figure 100k addressable pts for whom Sovaldi-based regimens cannot be used.

Good to know!